GlassScriptPhysician profile
Todd Bellamy
NPI 1093711137
$11,534.55
in general payments reported to CMS, 2019-2025
24 companies · $797 in 2025
The $797 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,488 · 2020: $1,398 · 2021: $3,145 · 2022: $1,182 · 2023: $1,363 · 2024: $1,161 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,321.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $2,270.29 | 2019-2023 | |
| Alcon Vision LLC | $1,827.87 | 2019-2025 | Precision 1, Total30, Tryptyr |
| Bausch & Lomb Americas INC. | $1,719.83 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,171.45 | 2019-2021 | |
| Coopervision INC. | $1,050.15 | 2019-2025 | Myday Contact Lens, Cvi Contact Lens, Misight Contact Lens |
| Allergan, INC. | $936.05 | 2019-2022 | |
| Abbvie INC. | $689.04 | 2022-2025 | Durysta |
| Eyevance Pharmaceuticals LLC | $312.55 | 2019-2021 | |
| Shire North American Group INC | $253.72 | 2019 | |
| Lkc Technologies, INC. | $193.03 | 2022 | |
| Dompe US, INC. | $176.71 | 2023-2024 | Oxervate |
| Sun Pharmaceutical Industries INC. | $131.05 | 2019-2023 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $130.59 | 2024 | Tecnis Simplicity |
| Oyster Point Pharma, INC. | $118.75 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $105.32 | 2024-2025 | Xdemvy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $95.76 | 2020-2023 | |
| Kala Pharmaceuticals, INC. | $82.34 | 2020-2022 | |
| Astellas Pharma US INC | $69.42 | 2024-2025 | Izervay |
| Staar Surgical Company | $47.96 | 2019 | |
| Maculogix, INC. | $42.73 | 2021 | |
| Aerie Pharmaceuticals, INC. | $41.29 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $27.06 | 2021 | |
| Sight Sciences, INC. | $22.19 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Bellamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.